“We are thrilled to partner with NeuroLogica and its leading mobile CT system at the forefront of MSU programs across the country,” said Anil Singhal, M.D., senior vice president, Worldwide Operations, at iSchemaView. “In addition, we are excited that our partnership allows the option of RAPID advanced imaging on CereToms in more than 500 ICUs worldwide.”
The CereTom is an eight-slice mobile CT scanner that delivers high-quality, non-contrast CT, CT angiography and CT perfusion scans in a variety of patient locations. RAPID is an advanced, fully automated and only clinically proven stroke imaging platform available. It provides intuitive and easily interpretable real-time views of brain perfusion and allows clear visualization of the cerebral arteries. In conjunction, their speed, ease-of-use and fast results make CereTom and RAPID indispensable tools for MSUs and ICUs, helping medical teams make life-saving triage, diagnostic and treatment decisions. RAPID is the only brain imaging platform that is U.S. Food and Drug Administration-cleared for selecting stroke patients for clot removal, also known as thrombectomy.
“By assessing patients in MSUs equipped with both CereTom and RAPID technologies, we will be able to swiftly identify the right course of action—on-site treatment with clot-busting agents or appropriate hospital transport for thrombectomy—thereby optimizing outcomes and quality of life,” said David Webster, chief operating officer at NeuroLogica.
Developed by stroke experts, RAPID combines unmatched expert features, proprietary algorithms and machine learning to deliver advanced stroke imaging and analysis. RAPID provides hypoperfusion, cerebral blood volume indexes, custom notifications and thresholding—including golden-hour thresholds. And RAPID is the only system that delivers results to mobile devices in less than 90 seconds, either by mobile app or email.
“This is a new frontier in stroke care. We are bringing technology directly to patients, no matter where they are. This allows us to make fast, accurate assessments of their clinical status and provide effective treatment directly in the MSU or transport the patient to the appropriate hospital for expedited clot removal,” said Dr. James Grotta, director of the Mobile Stroke Unit Consortium and director of Stroke Research for the Clinical Institute for Research and Innovation at the Memorial Herman–Texas Medical Center.
iSchemaView is a worldwide developer of advanced imaging for stroke. Installed in over 1,000 stroke centers, iSchemaView’s RAPID (automated CTP, MRI, CTA and ASPECTS), with enhanced AI framework, is the most advanced stroke imaging platform. In clinical trials, RAPID has been shown to aid in the selection of patients in early and late-window stroke trials, including SWIFT PRIME, EXTEND IA, DAWN, DEFUSE 3 and EXTEND. In addition to achieving the best clinical outcomes and largest treatment effects ever obtained, these studies led to new American Heart Association and American Stroke Association guidelines and have dramatically altered the management of acute stroke around the world.
NeuroLogica, a healthcare subsidiary of Samsung Electronics Co. Ltd., develops, manufactures, and markets imaging technologies and is committed to delivering fast, easy and accurate diagnostic solutions to healthcare providers. NeuroLogica, the global corporate headquarters and manufacturer of Samsung computed tomography, is also the U.S. headquarters for sales, marketing and distribution of all Samsung digital radiography and ultrasound systems. NeuroLogica’s growing portfolio of advanced medical technologies are used worldwide in healthcare institutions helping providers enhance patient care, improve patient satisfaction, and increase workflow efficiency.